Related Experiment Videos
Effect of tibolone on postmenopausal bone loss
J Rymer1, M G Chapman, I Fogelman
1Department of Obstetrics and Gynaecology, Guy's Hospital, London, UK.
Summary
Tibolone treatment significantly increased bone mass in postmenopausal women over two years, preventing bone loss seen in the control group. This study highlights tibolone
Area of Science:
- Endocrinology
- Bone Metabolism
- Gerontology
Background:
- Postmenopausal osteoporosis is a significant health concern.
- Hormone replacement therapy is a common treatment for menopausal symptoms and bone loss.
- Tibolone is a selective tissue estrogenic activity regulator (STEAR) with potential bone-protective effects.
Purpose of the Study:
- To assess the skeletal effects of tibolone in recently postmenopausal women.
- To evaluate changes in bone mineral density and biochemical markers of bone metabolism.
Main Methods:
- A 2-year non-randomized prospective study involving 100 postmenopausal women.
- Participants were divided into two groups: tibolone treatment (2.5 mg daily) and no medication (control).
- Bone densitometry (dual energy X-ray absorptiometry) and biochemical markers were assessed at baseline and 24 months.
Main Results:
- Tibolone group showed a significant increase in bone mineral density: 2.5% in the spine and 3.5% in the femoral neck.
- Control group experienced bone loss: 2.9% in the spine and 3.7% in the femoral neck.
- Tibolone treatment significantly reduced markers of bone turnover, including urinary hydroxyproline/creatinine and serum osteocalcin.
Conclusions:
- Tibolone effectively increases bone mass and reduces bone loss in recently postmenopausal women.
- The drug demonstrates a positive impact on bone metabolism, as evidenced by decreased bone turnover markers.
- Tibolone is a viable therapeutic option for managing skeletal health in postmenopausal women.